The review discusses 58 peptides in different clinical phases, indicating a strong pipeline of peptide therapies focusing on PPIs.Any possible conflicts of desire, for instance funding from pharmaceutical firms or private investments in connected industries, are comprehensively disclosed while in the research publications. This disclosure is vital